Reintubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy

Journal of Neonatal-Perinatal Medicine

Volumn 4, Issue 2, 2011, Pages 101-109

  Guardia, C G ^a,g   Moya, F R ^b   Sinha, S ^c   Gadzinowski, J ^d,e   Donn, S M ^f   Simmons, P ^g   Segal, R ^g  

^a UNIVERSITY OF CHILE   (Chile)

^b Department of Neonatology ^*  (United States)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g Discovery Laboratories Inc   (United States)

Author keywords

lucinactant; mortality; reintubation; Respiratory distress syndrome; surfactant

Indexed keywords

BERACTANT; CORTICOSTEROID; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; METHYLXANTHINE; PORACTANT;

AIR LEAK; ARTICLE; BRAIN HEMORRHAGE; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENCEPHALOMALACIA; ENDOTRACHEAL INTUBATION; EXTUBATION; FEMALE; HIGH RISK PATIENT; HUMAN; IATROGENIC DISEASE; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEWBORN MORBIDITY; PREMATURITY; PRIORITY JOURNAL; REINTUBATION; RESPIRATORY DISTRESS SYNDROME; RETROLENTAL FIBROPLASIA; SEPSIS; SURVIVAL RATE;

EID: 79959231624     PISSN: 19345798     EISSN: 18784429     Source Type: Journal    
DOI: 10.3233/NPM-2011-2736     Document Type: Article

References (17)

1. S. Korones, Complicationsofassisted ventilation, in: Assisted Ventilation of the Neonate, J. Goldsmith and E. Karotkin, eds, Saunders, 2003, pp. 345-377.
2. W. Carlo, R. Martin and A. Fanaroff, Assisted ventilation and complications of respiratory distress, in Neonatal-Perinatal Medicine, R. Martin and A. Fanaroff, eds, Mosby, 1997, pp. 1028-1040.
3. C.W. Seymour, A. Martinez, J.D. Christie and B.D. Fuchs, The outcome of extubation failure in a community hospital intensive care unit: a cohort study, Critical Care 8 (2004), 322-327.
4. S.K. Epstein, R.L. Ciubotaru and J.B. Wong, Effect of failed extubation on the outcome of mechanical ventilation, Chest 112 (1997), 186-192. (Pubitemid 27343617)
5. F.R. Moya, J. Gadzinowski, E. Bancalari, et al., For the international surfaxin collaborative study group. A multicenter, randomized, masked, comparison trial of lucinactant, colfos-ceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants, Pediatrics 115 (2005), 1018-1029.
6. S.K. Sinha, T. Lacaze-Masmonteil, A. Valls i Soler, et al., For the surfaxin therapy against respiratory distress syndrome collaborative group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk for respiratory distress syndrome, Pediatrics 115 (2005), 1030-1038.
7. F.R. Moya, S.K. Sinha, J. Gadzinowski, et al., One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials, Pediatrics J 119 (2007), e1361-e1370. (Pubitemid 46871256)
8. H. Verder, B. Robertson, G. Greisen, et al., Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-swedish Multi-center Study Group, N Engl J Med 331 (1994), 1051-1055. (Pubitemid 24317697)
9. C.J. Morley, P.G. Davis, L.W. Doyle, et al., Nasal CPAP or intubation at birth for very preterm infants, N Engl J Med 358 (2008), 700-708. (Pubitemid 351240749)
10. Vermont Oxford Network, Expanded Database Summary, Vermont Oxford Network 2006, Burlington, Vermont, 2005.
11. T.A. Merritt, et al., Reduction of the surface-tension-lowering ability of surfactant after exposure to hypochlorous acid, Biochem J 295 (1991), 19-22. (Pubitemid 23298302)
12. S. Andersson, A. Kheiter and T.A. Merritt, Oxidative inacti-vation of surfactants, Lung 177 (1999), 179-189.
13. J.D. Amirkhanian and T.A. Merritt, Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro fenton reaction, Lung 176 (1998), 63-72. (Pubitemid 28035974)
14. E. Manalo, T.A. Merritt, A. Kheiter, J. Amirkhanian and C. Cochrane, Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4, Pediatr Res 39 (1996), 947-952.
15. 4-surfactant prevents hyperoxic and LPS-induced lung injury in mice, Pediatr Pulmonol 41 (2006), 916-928. (Pubitemid 44534809)
16. ®) is associated with a reduction in bone morphogenetic protein (BMP) gene expression in a cell culture-based assay of lung inflammation, Presented at the Pediatric Academic Societies' Annual Meeting, 2007 May 5-8; Toronto, Canada. [abstract no. 750555]
17. Y. Zhu, T.L. Miller, A.C. Chidekel and T.H. Shaffer, KL4-surfactant (surfaxin®) protects human airway epithelium from hyperoxia, Pediatric Research 64 (2008), 154-158.